Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.40 |
| ▸ | HCN1 | O60741 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HCN4 | Q9Y3Q4 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402976 | 1.00 | BDKRB1 (0.40) | BDKRB1HCN1TP53HCN4MEN1 | |
| SCHEMBL3408612 | 0.85 | TP53 (0.40) | BDKRB1HCN1TP53HCN4MEN1 | |
| SCHEMBL3408994 | 0.81 | TP53 (0.45) | BDKRB1HCN1TP53HCN4MEN1 | |
| SCHEMBL3407674 | 0.79 | BDKRB1 (0.55) | BDKRB1TP53 | |
| SCHEMBL3405241 | 0.77 | TP53 (0.46) | BDKRB1HCN1TP53HCN4MEN1 | |
| SCHEMBL3406395 | 0.76 | TP53 (0.44) | BDKRB1HCN1TP53MEN1KMT2A | |
| SCHEMBL3409365 | 0.76 | BDKRB1 (0.51) | BDKRB1 | |
| SCHEMBL2564813 | 0.75 | BDKRB1 (0.59) | BDKRB1 | |
| SCHEMBL3402965 | 0.75 | TP53 (0.41) | BDKRB1HCN1TP53MEN1KMT2A | |
| SCHEMBL3402509 | 0.75 | HCN4 (0.37) | HCN1TP53HCN4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254867-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal Gmbh (DE) | 2010-12-01 | — | — | EP | claimed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | claimed |
| WO-2009109364-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-11 | — | — | WO | claimed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2254867-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal Gmbh (DE) | 2010-12-01 | — | — | EP | disclosed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009109364-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298812-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | BDKRB1 1/4885HCN1 426/4885TP53 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.